Psychosis

Those with first-episode psychosis demonstrated more suicidal behavior compared with healthy controls, while perceived stress and emotional abuse were linked to an increase in suicidal ideation and risk, according to a recent study.

Acadia Pharmaceuticals Inc. announced the outcome of the FDA advisory committee meeting on the use of pimavanserin for treating hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

Acadia Pharmaceuticals Inc. has resubmitted its supplemental new drug application to the FDA for pimavanserin for treating hallucinations and delusions linked to Alzheimer’s disease psychosis.

Cognitive function and clinical insight play significant roles in mediating symptoms for those with first-episode psychosis, according to a study published in the Journal of Psychiatric Research.

Vitamin D supplementation did not appear linked to mental health or metabolic outcomes at 6 months in people with first-episode psychosis, according to results of a randomized clinical trial published in JAMA Network Open.

Areas with high levels of social fragmentation had higher rates of psychosis, according to results of a systematic review published in Journal of Clinical Psychiatry.

Loneliness may signal underlying psychotic experiences among adolescents, according to results of a population-based birth cohort study published in Schizophrenia Research.

Neurocrine Biosciences and Sosei Group Corporation have announced a partnership to create a new brand of protein inhibitor that the former plans to study to improve treatments for a wide range of neuropsychiatric disorders.

Clinical high risk for psychosis syndrome appeared linked to impairment in reciprocal social behavior, according to results of a cross-sectional study published in Psychiatry Research.